ECDC, EFSA and EMA Joint Scientific Opinion on a list of outcome indicators as regards surveillance of antimicrobial resistance and antimicrobial consumption in humans and food‐producing animals

Abstract ECDC, EFSA and EMA have jointly established a list of harmonised outcome indicators to assist EU Member States in assessing their progress in reducing the use of antimicrobials and antimicrobial resistance (AMR) in both humans and food‐producing animals. The proposed indicators have been selected on the basis of data collected by Member States at the time of publication. For humans, the proposed indicators for antimicrobial consumption are: total consumption of antimicrobials (limited to antibacterials for systemic use), ratio of community consumption of certain classes of broad‐spectrum to narrow‐spectrum antimicrobials and consumption of selected broad‐spectrum antimicrobials used in healthcare settings. The proposed indicators for AMR in humans are: meticillin‐resistant Staphylococcus aureus and 3rd‐generation cephalosporin‐resistant Escherichia coli, Klebsiella pneumoniae resistant to aminoglycosides, fluoroquinolones and 3rd‐generation cephalosporins, Streptococcus pneumoniae resistant to penicillin and S. pneumoniae resistant to macrolides, and K. pneumoniae resistant to carbapenems. For food‐producing animals, indicators for antimicrobial consumption include: overall sales of veterinary antimicrobials, sales of 3rd‐ and 4th‐generation cephalosporins, sales of quinolones and sales of polymyxins. Finally, proposed indicators for AMR in food‐producing animals are: full susceptibility to a predefined panel of antimicrobials in E. coli, proportion of samples containing ESBL‐/AmpC‐producing E. coli, resistance to three or more antimicrobial classes in E. coli and resistance to ciprofloxacin in E. coli. For all sectors, the chosen indicators, which should be reconsidered at least every 5 years, are expected to be valid tools in monitoring antimicrobial consumption and AMR. With the exception of the proposed human AMR indicators, the indicators are in general not suitable to monitor the effects of targeted interventions in a specific sector, such as in a single animal species or animal production sector. Management decisions should never be based on these indicators alone but should take into account the underlying data and their analysis.

Stephen C. Spiteri | N. Speybroeck | B. Nørrung | Christine Schwarz | M. Sanaa | J. Reilly | R. Girones | E. Snary | A. Ricci | J. Threlfall | P. Skandamis | S. Hopkins | K. Koutsoumanis | L. Robertson | P. Pasquali | A. Allende | D. Bolton | M. Chemaly | R. Davies | R. Lindqvist | G. Ru | Marion M Simmons | L. Herman | V. Jarlier | E. Liébana | R. Strauss | B. Catry | J. Weeks | D. Monnet | C. Greko | D. Plachouras | B. Tenhagen | P. Zarb | O. Vandenberg | A. Wester | D. Murphy | Zanda Auce | J. Beechinor | H. Bergendahl | R. Breathnach | J. Bureš | Judita Hederova | P. Hekman | Emil Iliev Kozhuharov | G. Kulcsar | Johann M. Lenhardsson | P. Mačiulskis | Ioannis Malemis | Alia Michaelidou-Patsia | M. Nevalainen | Jean-Claude Rouby | W. Schlumbohm | M. Schmit | Lollita Sanda Camelia Taban | T. Tiirats | B. Urbain | E. Vestergaard | K. Baptiste | P. Sanders | Z. Kunsági | P. Stella | H. Jukes | M. Rantala | M. Moreno | C. Pomba | M. Cormican | O. Heuer | E. Iosifidis | K. Weist | G. Moulin | Kristine Ignate | G. S. Simonsen | M. Ruzauskas | J. Torren-Edo | C. Teale | P. Beloeil | K. Grave | D. Żabicka | F. Božić | D. Bouchard | P. F. Escámez | B. T. Kuile | G. J. Schefferlie | M. Catchpole | E. Duijkeren | M. Simmons | H. Wahlstroem | Gertraud Schueepbach | Brigitte Hauser | G. Hahn | Anna Wachnik Swiezcicka | Joao Pedro Duarte Da Silva | Katarina Straus | Cristina Muñoz Madero | Eva Persson | Katariina Kivilahti-Mäntylä | Juergen Wallmann | B. Kuile | E. V. Duijkeren | Kostas Koutsoumanis

[1]  B. Henriques-Normark,et al.  Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study. , 2017, The Lancet. Respiratory medicine.

[2]  Chantal Quinten,et al.  ECDC/EFSA/EMA second joint report on the integrated analysis of the consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food‐producing animals , 2017, EFSA journal. European Food Safety Authority.

[3]  J. Dewulf,et al.  Guidance on the Selection of Appropriate Indicators for Quantification of Antimicrobial Usage in Humans and Animals , 2017, Zoonoses and public health.

[4]  G. Dantas,et al.  Next-generation approaches to understand and combat the antibiotic resistome , 2017, Nature Reviews Microbiology.

[5]  A. Meleshko,et al.  Phase I clinical trial of idiotypic DNA vaccine administered as a complex with polyethylenimine to patients with B-cell lymphoma , 2017, Human vaccines & immunotherapeutics.

[6]  E. Cytryn,et al.  Impact of anthropogenic activities on the dissemination of antibiotic resistance across ecological boundaries. , 2017, Essays in biochemistry.

[7]  J. Jansen,et al.  The RESET Mindset Model applied on decreasing antibiotic usage in dairy cattle in the Netherlands , 2017, Irish Veterinary Journal.

[8]  G. Schüpbach-Regula,et al.  Approaches for quantifying antimicrobial consumption per animal species based on national sales data: a Swiss example, 2006 to 2013 , 2017, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[9]  Stephen C. Spiteri,et al.  EMA and EFSA Joint Scientific Opinion on measures to reduce the need to use antimicrobial agents in animal husbandry in the European Union, and the resulting impacts on food safety (RONAFA) , 2017, EFSA journal. European Food Safety Authority.

[10]  M. Moreira,et al.  A reflection on invasive pneumococcal disease and pneumococcal conjugate vaccination coverage in children in Southern Europe (2009–2016) , 2016, Human vaccines & immunotherapeutics.

[11]  E. J. Threlfall,et al.  Public health risk of antimicrobial resistance transfer from companion animals. , 2016, The Journal of antimicrobial chemotherapy.

[12]  Jonathan Rushton,et al.  A One Health approach to antimicrobial resistance surveillance: is there a business case for it? , 2016, International journal of antimicrobial agents.

[13]  S. Brul,et al.  The risk of low concentrations of antibiotics in agriculture for resistance in human health care. , 2016, FEMS microbiology letters.

[14]  M. Fuzi Dissimilar Fitness Associated with Resistance to Fluoroquinolones Influences Clonal Dynamics of Various Multiresistant Bacteria , 2016, Front. Microbiol..

[15]  G. Kourlaba,et al.  Antibiotic prescribing and expenditures in outpatient adults in Greece, 2010 to 2013: evidence from real-world practice. , 2016, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[16]  J. Vincent,et al.  Antibiotic strategies in the era of multidrug resistance , 2016, Critical Care.

[17]  J. Vila,et al.  What is the clinical relevance of drug-resistant pneumococcus? , 2016, Current opinion in pulmonary medicine.

[18]  L. McGee,et al.  Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective , 2016, Clinical Microbiology Reviews.

[19]  D. Mackay,et al.  The management of risk arising from the use of antimicrobial agents in veterinary medicine in EU/EEA countries - a review. , 2015, Journal of veterinary pharmacology and therapeutics.

[20]  M. Jonker,et al.  Factors That Affect Transfer of the IncI1 β-Lactam Resistance Plasmid pESBL-283 between E. coli Strains , 2015, PloS one.

[21]  V. Economou,et al.  Agriculture and food animals as a source of antimicrobial-resistant bacteria , 2015, Infection and drug resistance.

[22]  M. Pérez-Vázquez,et al.  Evolution of carbapenemase-producing Enterobacteriaceae at the global and national level: what should be expected in the future? , 2014, Enfermedades infecciosas y microbiologia clinica.

[23]  L. Kreienbrock,et al.  Subgrouping of ESBL-producing Escherichia coli from animal and human sources: an approach to quantify the distribution of ESBL types between different reservoirs. , 2014, International journal of medical microbiology : IJMM.

[24]  F. Aarestrup,et al.  Characterization of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli obtained from Danish pigs, pig farmers and their families from farms with high or no consumption of third- or fourth-generation cephalosporins. , 2014, The Journal of antimicrobial chemotherapy.

[25]  Bryan T Grenfell,et al.  Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. , 2014, The Lancet. Infectious diseases.

[26]  S. Simjee,et al.  Antimicrobial resistance monitoring projects for zoonotic and indicator bacteria of animal origin: common aspects and differences between EASSA and EFSA. , 2014, Veterinary microbiology.

[27]  J. M. Schuurmans,et al.  Interaction between Mutations and Regulation of Gene Expression during Development of De Novo Antibiotic Resistance , 2014, Antimicrobial Agents and Chemotherapy.

[28]  J. Martínez General principles of antibiotic resistance in bacteria. , 2014, Drug discovery today. Technologies.

[29]  J. Dewulf,et al.  Correlation between veterinary antimicrobial use and antimicrobial resistance in food-producing animals: a report on seven countries. , 2014, The Journal of antimicrobial chemotherapy.

[30]  A. Pimenta,et al.  Evolution of drug resistance: insight on TEM β-lactamases structure and activity and β-lactam antibiotics. , 2014, Mini reviews in medicinal chemistry.

[31]  J. Wagenaar,et al.  Antimicrobial resistance in commensal Escherichia coli in veal calves is associated with antimicrobial drug use , 2013, Epidemiology and Infection.

[32]  M. Struelens,et al.  Development and validation of potential structure indicators for evaluating antimicrobial stewardship programmes in European hospitals , 2013, European Journal of Clinical Microbiology and Infectious Diseases.

[33]  L. Randall,et al.  Characteristics of ciprofloxacin and cephalosporin resistant Escherichia coli isolated from turkeys in Great Britain , 2013, British poultry science.

[34]  R. Porcher,et al.  Reduction of fluoroquinolone use is associated with a decrease in methicillin-resistant Staphylococcus aureus and fluoroquinolone-resistant Pseudomonas aeruginosa isolation rates: a 10 year study. , 2012, The Journal of antimicrobial chemotherapy.

[35]  M. Wilcox,et al.  MRSA prevention strategies and current guidelines. , 2011, Injury.

[36]  H. Goossens,et al.  European Surveillance of Antimicrobial Consumption (ESAC): quality appraisal of antibiotic use in Europe. , 2011, The Journal of antimicrobial chemotherapy.

[37]  R. Laxminarayan,et al.  Communicating trends in resistance using a drug resistance index , 2011, BMJ Open.

[38]  Y. Chong,et al.  Genetic evolution and clinical impact in extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. , 2011, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[39]  M. Falagas,et al.  Extended-spectrum b-lactamase-producing organisms , 2022 .

[40]  F. Aarestrup,et al.  Selection and Persistence of CTX-M-Producing Escherichia coli in the Intestinal Flora of Pigs Treated with Amoxicillin, Ceftiofur, or Cefquinome , 2008, Antimicrobial Agents and Chemotherapy.

[41]  Herman Goossens,et al.  European Surveillance of Antimicrobial Consumption (ESAC): quality indicators for outpatient antibiotic use in Europe , 2007, Quality & Safety in Health Care.

[42]  D. Henderson,et al.  Managing methicillin-resistant staphylococci: a paradigm for preventing nosocomial transmission of resistant organisms. , 2006, American journal of infection control.

[43]  S. Salmaso,et al.  Pneumococcal vaccination policy in Europe. , 2005, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[44]  D. Smith,et al.  Decreased Antimicrobial Resistance after Changes in Antibiotic Use , 1999, Pharmacotherapy.

[45]  P Huovinen,et al.  The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. , 1997, The New England journal of medicine.

[46]  N. Mittmann,et al.  Impact of infection with extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella species on outcome and hospitalization costs. , 2016, The Journal of hospital infection.

[47]  Daniel J. Shapiro,et al.  Antibiotic prescribing for adults in ambulatory care in the USA, 2007-09. , 2014, The Journal of antimicrobial chemotherapy.

[48]  de Greeff Sc,et al.  NethMap 2017: Consumption of antimicrobial agents and antimicrobial resistance among medically important bacteria in the Netherlands / MARAN 2017: Monitoring of antimicrobial resistance and antibiotic usage in animals in the Netherlands in 2016 , 2012 .